Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc demonstrated strong financial performance with a 21% increase in top-line growth during Q3, driven by a 13% rise in volumes and a 5% lift in average selling prices. The company achieved its highest cash collections in October and reported positive GAAP net income while raising both top and bottom line guidance, reflecting an optimistic outlook. Furthermore, with a recent 50% expansion of its sales force, CareDx is positioned for sustained volume growth moving forward, particularly following a solid 19% year-over-year increase in kidney surveillance volumes recorded earlier in the year.

Bears say

CareDx Inc reported Q3'25 test volumes of 50,000, which, despite a year-over-year increase of 13%, fell short of expectations, indicating potential stagnation, particularly in the autumn months. The company's shares have faced significant pressure, trading at 1.4 times projected revenue for 2026, which is substantially below historical averages and other diagnostic peers. Additionally, CareDx is grappling with concerns regarding its ability to successfully commercialize new diagnostic solutions, compounded by ongoing management turnover that may further hinder its growth strategy.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.